Modalis Therapeutics Corporation (4883.T)
JPY 75.0
(-1.32%)
JPY 75.0
(-1.32%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.47 Billion JPY | 49.85% |
| 2022 | -2.93 Billion JPY | 40.58% |
| 2021 | -4.93 Billion JPY | 8.95% |
| 2020 | -5.42 Billion JPY | -40.56% |
| 2019 | -3.85 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.05 Billion JPY | 28.55% |
| 2024 Q2 | -1.11 Billion JPY | -6.17% |
| 2023 FY | -1.47 Billion JPY | 49.85% |
| 2023 Q3 | -1.89 Billion JPY | 26.79% |
| 2023 Q1 | -2.7 Billion JPY | 7.67% |
| 2023 Q4 | -1.47 Billion JPY | 22.46% |
| 2023 Q2 | -2.59 Billion JPY | 4.31% |
| 2022 Q3 | -3.68 Billion JPY | 0.0% |
| 2022 Q4 | -2.93 Billion JPY | 20.33% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 220.076% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.034% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 100.377% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 99.575% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 58.729% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 96.511% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 97.607% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 98.498% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -120.53% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 97.162% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 95.532% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 119.349% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 118.904% |
| Tsumura & Co. | 1.61 Billion JPY | 191.08% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 96.669% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 95.729% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 100.852% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 105.525% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 105.075% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 120.835% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 308.94% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 124.548% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 77.429% |
| MedRx Co., Ltd | -1.72 Billion JPY | 14.48% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 83.125% |
| Solasia Pharma K.K. | -668 Million JPY | -120.2% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 79.72% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 102.602% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 50.319% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 98.506% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 86.784% |